TP53-deficient acute myeloid leukemia (AML) in human is highly malignant, has a low response rate to chemotherapy, and has a mediate overall survival of only 5-10 months (66), so there is an urgent need for effective animal models to develop new treatments. Here, TP53 is linked to acute myeloid leukemia.